Feb 9 2010
Kamada, a bio-pharmaceutical company engaged in the development,
manufacturing and marketing of specialty life-saving therapeutics,
announced today that it has enrolled the first patient into its pivotal
clinical trial with its new breakthrough compound of inhaled alpha-1
antitrypsin (AAT) delivered by an Investigational eFlow Nebulizer System
(PARI Pharma GmbH), in patients with alpha-1 antitrypsin deficiency.
The Phase 2-3, multi-center, randomized, double-blind,
placebo-controlled and international study will evaluate the efficacy
and safety of inhaled, human AAT in alpha-1 deficient patients with
emphysema. The trial will be conducted across several European
countries. The study protocol has been designed in agreement with the
EMEA under the product's orphan drug designation status.
David Tsur, Chief Executive Officer of Kamada said, “We are very pleased
with the advancement of the trial and hope that the rate of enrollment
would reflect the excitement of the patients of this potential new
treatment. We recognize the importance of bringing this product to this
unique patient population for whom, at the moment, there is no
therapeutic resolution.
HIV trial points to semaglutide as a new anti-aging contender